azd7295
Small moleculeexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00522808)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- a-831
- a-831
- azd7295
- azd7295
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01097408 | Phase 1 | Mar 1, 2010 | Arrow Therapeutics, Quotient |
| NCT00906256 | Phase 1 | Apr 1, 2009 | Arrow Therapeutics |
| NCT00818129 | Phase 1 | Dec 1, 2008 | AstraZeneca, Kyushu Clinical Pharmacolgy Reasearch Clinic |
| NCT00781976 | Phase 1 | Nov 1, 2008 | Arrow Therapeutics, Auckland Clinical Studies |
| NCT00522808 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2007 | Arrow Therapeutics, Auckland Clinical Studies, University of Birmingham, Wellcome Trust |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arrow Therapeutics | For profit | 4 | 4 | 2 | 2007 |
| Auckland Clinical Studies | For profit | 2 | 0 | 2 | 2007 |
| AstraZeneca | For profit | 1 | 1 | 1 | 2008 |
| Kyushu Clinical Pharmacolgy Reasearch Clinic | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Quotient | For profit | 1 | 0 | 1 | 2010 |
| University of Birmingham | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Wellcome Trust | Academic/Hospital | 1 | 0 | 1 | 2007 |
7 organizations
Page 1 / 1